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Introduction
Angiogenesis is a physiological phenomenon in which new vascular branches arise from the existing blood vessels [1] . Individually and by interacting with each other, vascular endothelial cells repeatedly conduct the following actions, namely, budding, elongation, and lumen and bridge formation, resulting in the generation of an organized blood vessel network in three dimensions [2] . The cell dynamics in angiogenesis are regulated comprehensively. Though essential for some physiological conditions, such as embryonic development, wound healing, and tissue regeneration, angiogenesis is also involved critically in diverse pathological conditions, including growth and invasion of carcinomas, ischemic heart diseases, and retinal degenerative diseases.
Vascular endothelial growth factor (VEGF), which is a representative angiogenesis inducer, promotes migration and proliferation of vascular endothelial cells [3] . VEGF receptor is expressed specifically on vascular endothelial cells and its expression correlates with tumor progression and poor prognosis in patients with cancer, such as gastric cancer [4] [5] [6] and lung cancer [7] [8] [9] . Correspondingly, anti-VEGF antibody is used as a therapeutic agent against such cancers.
Brain-derived neurotrophic factor (BDNF) is a humoral protein that binds to a receptor called tropomyosin receptor kinase B (TrkB) on nerve cells and then induces growth of neurons [10] . It has been demonstrated that the BDNF signal through TrkB also induced growth of cells other than nerve cells; e.g., vascular endothelial cells [11] [12] [13] . Recent studies have suggested that BDNF could act as an angiogenesis inducer similar to VEGF [14, 15] . Although some reports suggest the activation of VEGF by BDNF [16] [17] [18] , the precise mechanism of angiogenicity remains unrevealed.
Angiogenin, a strong mediator of angiogenesis, was isolated from the culture supernatant of the HT-29 human colon cancer cell line [16] . It has particular characteristics both as a secreted protein and a transcription factor. After being incorporated into the cytoplasm, angiogenin is immediately transferred to the nucleus and then mediates the angiogenic effects of angiogenesis inducers, including VEGF [19, 20] . Correspondingly, inhibition of the nuclear translocation of angiogenin has been shown to suppress the angiogenesis.
Several factors are notably involved in the angiogenesis. Although it becomes clearer that angiogenin plays a role in the downstream of the angiogenesis inducers, there is no report that focuses on the association between BDNF and angiogenin. In the present study, we attempted to determine the effects of BDNF on the dynamics of angiogenin.
Materials and methods

Cell culture
Human umbilical vein endothelial cells (HUVEC) purchased from Lonza (Basel, Switzerland) were cultured in HuMedia-EG2 (Kurabo, Osaka, Japan) with supplement of 2% fetal bovine serum at 37 ºC in a humidified atmosphere with 5% CO 2 .
A fresh medium was replaced every 48 h. Cells within passages guaranteed by the supplier were used for experiments. Prior to the experiments, cells were washed three times with serum-free EBM-2 medium (Lonza) in order to avoid the influences of putative angiogenic factors in the culture medium.
Reagents
Recombinant human VEGF and BDNF and neomycin were purchased from Wako Pure Chemical Industries (Osaka, Japan).
Enzyme-linked immunosorbent assay (ELISA) to quantify angiogenin
HUVEC were grown up to 60-70% confluency in 24-well plates. After washing, the cells were incubated with BDNF (0, 5, 25, 50, 200, 500, and 1,000 ng/mL) dissolved in EBM-2 for 24 h at 37 ºC. Thereafter, the culture supernatant was collected and subjected to enzyme-linked immunosorbent assay (ELISA) for quantification of angiogenin using Human Angiogenin Quantikine ELISA Kit (R&D Systems, Minneapolis, USA) according to the manufacturer's instructions. Similar experiments were repeated more than three times. Each measurement was carried out in duplicates.
Lactate dehydrogenase (LDH) release assay
HUVEC (2.5 × 10 4 /well of 96-well plates) were exposed to 0, 15.625, 31.25, 62.5, 125, 250, 500, or 1000 ng/mL of BDNF at 37 ºC. After 48 h, lactate dehydrogenase (LDH) release from the HUVEC was determined using Cytotoxicity LDH Release Assay Kit (Dojindo, Kumamoto, Japan). Assay was carried out in triplicates. Percent cytotoxicity was determined according to the manufacturer's protocol.
Immunofluorescent staining of angiogenin
HUVEC were grown up to about 60% confluency in 4-well chamber slides (Corning, Corning, USA). After washing, the cells were incubated in EBM-2 without stimulant (as negative control), with 10 ng/mL of VEGF (as positive control), or with 1 µg/mL of BDNF for 4 h at 37 ºC. Thereafter, the cells were fixed with cold methanol for 10 min. After removal of methanol, the cells were washed three times with PBS. Next, in order to block non-specific binding of antibodies, the cells were soaked in PBS containing bovine serum albumin (BSA) (30 mg/mL) for 1 h at room temperature.
Following these preparations, immunofluorescent staining of angiogenin was carried out. For this purpose, anti-human angiogenin monoclonal antibody (MANG1, mouse IgM) (BMA Biomedicals, Augst, Switzerland) was used as a primary antibody. The primary antibody was diluted to 50 μg/mL in the BSA-containing PBS, and the cells were allowed to react with the diluted primary antibody for 1 h at room temperature (alternatively, overnight at 4 °C). After washing three times with PBS, the cells were next allowed to react with Alexa Fluor 488-labeled goat anti-mouse IgM antibody (Abcam, Cambridge, UK) for 30 min at room temperature in the dark. The secondary antibody was diluted to 10 μg/mL in the BSA-containing PBS. After washing three times with PBS followed by removal of the chambers, the cells were mounted using VECTASHIELD Mounting Medium containing 4',6-diamidino-2-phenylindole (DAPI) (VECTOR Laboratories, Burlingame, USA). These slides were observed under a fluorescent microscopy. Similar experiments were repeated more than three times.
Photomicrographs
After verifying the general state of staining under low power fields of view, photomicrographs were taken using Nikon NIS-Elements software (Tokyo, Japan).
Angiogenin granules in the nucleus were counted concerning 20 cells and then the counts per nucleus were calculated.
Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR)
HUVEC were grown up to about 60% confluency in 6 cm dishes. After washing, the cells were incubated in EBM-2 without stimulant (as negative control), with 10 ng/mL of VEGF (as positive control), or with 1 µg/mL of BDNF for 4 h at 37 ºC. Alternatively, HUVEC were treated with 1 µg/mL of BDNF at 37 ºC for 1, 4, or 24 h. Relative mRNA expression of angiogenin was determined by the comparative Ct method. Similar experiments were repeated more than three times. Each PCR was carried out in triplicates.
BDNF-induced Proliferation of HUVEC and effects of inhibitor of angiogenin nuclear translocation
HUVEC were grown up to about 60% confluency in 3.5 cm dishes. After washing, the cells were incubated in EBM-2 without stimulant (as negative control), with 1 µg/mL of BDNF, 100 µM of neomycin, or both BDNF (1 µg/mL) and neomycin (100 µM) at 37 ºC. Neomycin, an aminoglycoside antibiotic, has been shown as a specific inhibitor of nuclear translocation of angiogenin [21] . After 24 h, the cell number was counted. Simultaneously, immunofluorescent staining for angiogenin was carried out as aforementioned. Similar experiments were repeated three times.
Statistical analysis
Data were compared using Student's t-test according to the difference in variance determined by the F-test. The p-values of less than 0.05 were regarded as significant.
Results
Secretion of angiogenin from HUVEC by BDNF stimulation
Secretion of angiogenin from HUVEC by BDNF stimulation for 24 h was determined using the ELISA kit. The concentration of angiogenin in the culture supernatants was increased by BDNF dose-dependently and was significantly higher in the supernatants of HUVEC stimulated by 1 µg/mL of BDNF than in the HUVEC without stimulation (Figure 1a) . No significant release of LDH from the HUVEC treated with BDNF (even at the concentration of 1 µg/mL for 48 h) was evident (Figure   1b) . The presence of angiogenin in the supernatant as a result of BDNF cytotoxicity to HUVEC is ruled out. These findings indicate that BDNF can induce secretion of angiogenin from HUVEC.
Nuclear translocation of angiogenin by BDNF stimulation
In order to determine that BDNF could induce translocation of angiogenin into the nucleus, immunofluorescent staining for angiogenin was conducted on HUVEC stimulated by 1 µg/mL of BDNF for 4 h. For positive control, HUVEC stimulated by 10 ng/mL of VEGF were employed. As shown in Figure 2a , fluorescent granules that represented angiogenin were observed in the nuclei of HUVEC stimulated by VEGF.
This finding is consistent with the previous report that demonstrates the nuclear translocation of angiogenin induced by VEGF [19] . Similarly, fluorescent granules that represented angiogenin were observed in the nuclei of HUVEC stimulated by BDNF though the cytoplasmic staining for angiogenin was much fainter compared with HUVEC stimulated by VEGF. The numbers of angiogenin granules were 22.05/nucleus of the HUVEC stimulated by BDNF and 15.94/nucleus of the HUVEC stimulated by VEGF, and they were significantly greater than in the HUVEC without stimulation (9.29/nucleus) (Figure 2b) .
On the other hand, the mRNA expression level of angiogenin was not significantly altered in HUVEC by stimulation with VEGF (10 ng/mL) or BDNF (1 µg/mL) for 4 h (Figure 3a) . In addition, the angiogenin mRNA expression was not significantly altered up to 24 h after stimulation with BDNF (1 µg/mL) (Figure 3b) .
The collective findings suggest that both VEGF and BDNF can induce nuclear translocation of angiogenin in HUVEC without a significant increase in the mRNA expression.
Involvement of angiogenin nuclear translocation in BDNF-induced HUVEC proliferation
In order to determine the involvement of angiogenin nuclear translocation in BDNF-induced angiogenesis, we conducted an experiment using neomycin, a specific inhibitor of nuclear translocation of angiogenin [21] . We demonstrated that BDNF could induce proliferation of HUVEC and the BDNF-induced proliferation was significantly suppressed when the nuclear translocation of angiogenin was inhibited by neomycin (Figure 4) . These findings indicate that nuclear translocation of angiogenin is critically involved in BDNF-induced proliferation of HUVEC.
Discussion
In the present study, we have demonstrated that BDNF could induce angiogenin secretion and nuclear translocation without a significant increase in the mRNA expression and that nuclear translocation of angiogenin is critically involved in The mRNA expression analysis in HUVEC after BDNF stimulation has revealed that BDNF did not augment the angiogenin mRNA expression in HUVEC similar to VEGF. Although the angiogenin gene locates in the middle of the RNase A superfamily gene cluster, the ribonuclease activity is reported to be very low [24] . In (b) LDH release from HUVEC exposed to BDNF for 48 h determined using Cytotoxicity LDH Release Assay Kit. Data are presented as percent cytotoxicity. Simultaneously, immunofluorescent staining for angiogenin was carried out.
